Diverse Regulation of Cardiac Expression of Relaxin Receptor by α1- and β1-Adrenoceptors

Epac2 Mediates Cardiac β1-Adrenergic–Dependent Sarcoplasmic Reticulum Ca 2+ Leak and Arrhythmia

(2013) Laëtitia Pereira et al.   CIRCULATION

Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts

(2013) Ashish Parikh et al.   CIRCULATION RESEARCH

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF

(2013) M. Metra et al.   EUROPEAN HEART JOURNAL

Relaxin Family Peptides and Their Receptors

(2013) R. A. D. Bathgate et al.   PHYSIOLOGICAL REVIEWS

Benefits of   blockers in patients with heart failure and reduced ejection fraction: network meta-analysis

(2013) S. Chatterjee et al.   BMJ-British Medical Journal

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

Novel Role of Platelets in Mediating Inflammatory Responses and Ventricular Rupture or Remodeling Following Myocardial Infarction

(2011) Yang Liu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Progesterone Withdrawal, and Not Increased Circulating Relaxin, Mediates the Decrease in Myometrial Relaxin Receptor (RXFP1) Expression in Late Gestation in Rats1

(2010) Lenka A. Vodstrcil et al.   BIOLOGY OF REPRODUCTION

Myocardial oxidative stress contributes to transgenic β2-adrenoceptor activation-induced cardiomyopathy and heart failure

(2010) Q Xu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Relaxin

(2010) Jason Grossman et al.   Cardiology in Review

Relaxin Therapy Reverses Large Artery Remodeling and Improves Arterial Compliance in Senescent Spontaneously Hypertensive Rats

(2010) Qi Xu et al.   HYPERTENSION

Unveiling the Vasodilatory Actions and Mechanisms of Relaxin

(2010) Kirk P. Conrad   HYPERTENSION

The Positive Inotropic Effect of Relaxin-2 in Human Atrial Myocardium is Preserved in End-Stage Heart Failure: Role of Gi-Phosphoinositide-3 Kinase Signaling

(2010) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

β-Arrestin: A signaling molecule and potential therapeutic target for heart failure

(2010) Nabila Noor et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure

(2010) Brian C. Jensen et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

α1-Adrenergic Activation Upregulates Expression of Relaxin Receptor RXFP1 in Cardiomyocytes

(2009) Xiao-Lei Moore et al.   Annals of the New York Academy of Sciences

Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial

(2009) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

Cardiovascular effects of relaxin: from basic science to clinical therapy

(2009) Xiao-Jun Du et al.   Nature Reviews Cardiology

A Novel Protein Kinase A-independent, β-Arrestin-1-dependent Signaling Pathway for p38 Mitogen-activated Protein Kinase Activation by β2-Adrenergic Receptors

(2008) Kaizheng Gong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Relaxin (RLX) and estrogen affect estrogen receptor α, vascular endothelial growth factor, and RLX receptor expression in the neonatal porcine uterus and cervix

(2008) Wenbo Yan et al.   REPRODUCTION